Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 3, 2012, Pages 662-668

  Castro, Michele M ^a   Cena, Jonathan ^a   Cho, Woo Jung ^b   Walsh, Michael P ^c   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PRINCETON UNIVERSITY   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

calponin 1; endotoxemia; lipopolysaccharide; metalloproteinases; vascular hypocontractility

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; BACTERIUM LIPOPOLYSACCHARIDE; CALPONIN; DOXYCYCLINE; GELATINASE A; NITRATE; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSOLIC FRACTION; ENDOTOXEMIA; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; MUSCLE CELL; NITRATE UPTAKE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; VASCULAR DISEASE; VASCULAR HYPOCONTRACTILITY; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; ENDOTOXEMIA; GLUTATHIONE; IMMUNOPRECIPITATION; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 2; MICROFILAMENT PROTEINS; MUSCLE, SMOOTH, VASCULAR; PHENYL ETHERS; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84857642522     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.242685     Document Type: Article

References (48)

1. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth. 2001;15:364-376. (Pubitemid 32553389)
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29:1303-1310. (Pubitemid 32641789)
3. Matsuda N, Hattori Y. Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res. 2007;43:117-137.
4. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett. 1990;275:87-90. (Pubitemid 20386182)
5. Rees DD, Cellek S, Palmer RM, Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun. 1990;173:541-547.
6. Szabo C, Salzman AL, Ischiropoulos H. Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett. 1995;363:235-238.
7. Cuzzocrea S, Mazzon E, Di Paola R, Esposito E, Macarthur H, Matuschak GM, Salvemini D. A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther. 2006;319:73-81. (Pubitemid 44455112)
8. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem. 2001;276: 29596-29602.
9. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, Leon H, van Mulligen T, Schulz R. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol. 2009;77:826-834.
10. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90: 251-262. (Pubitemid 34633925)
11. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol. 2007; 152:189-205. (Pubitemid 47517601)
12. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75:346-359. (Pubitemid 350298459)
13. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis. 2008;198:320-331. (Pubitemid 351707391)
14. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res. 2000;46:225-238. (Pubitemid 30204594)
15. Chung AW, Au Yeung K, Sandor GG, Judge DP, Dietz HC, van Breemen C. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and-9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res. 2007;101:512-522. (Pubitemid 47351231)
16. Chung AW, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and-9. Circ Res. 2008;102:e73-e85. (Pubitemid 351591557)
17. Lalu MM, Cena J, Chowdhury R, Lam A, Schulz R. Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction. Br J Pharmacol. 2006;149:31-42. (Pubitemid 44299066)
18. Cena JJ, Lalu MM, Cho WJ, Chow AK, Bagdan ML, Daniel EE, Castro MM, Schulz R. Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia. Am J Physiol Heart Circ Physiol. 2010;298:H45-H51.
19. Carney DE, McCann UG, Schiller HJ, Gatto LA, Steinberg J, Picone AL, Nieman GF. Metalloproteinase inhibition prevents acute respiratory distress syndrome. J Surg Res. 2001;99:245-252. (Pubitemid 32703443)
20. Maitra SR, Bhaduri S, Valane PD, Tervahartiala T, Sorsa T, Ramamurthy N. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock. 2003;20:280-285.
21. Steinberg J, Halter J, Schiller H, Gatto L, Carney D, Lee HM, Golub L, Nieman G. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock. 2005;24:348-356. (Pubitemid 41416521)
22. Halter JM, Pavone LA, Steinberg JM, Gatto LA, DiRocco J, Landas S, Nieman GF. Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture. Shock. 2006;26:587-591. (Pubitemid 44789633)
23. Steinberg J, Halter J, Schiller HJ, Dasilva M, Landas S, Gatto LA, Maisi P, Sorsa T, Rajamaki M, Lee HM, Nieman GF. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res. 2003;111:185-195. (Pubitemid 36808908)
24. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007;47:211-242.
25. Cauwe B, Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2010;45:351-423.
26. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106:1543-1549.
27. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation. 2005;112:544-552. (Pubitemid 41060795)
28. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alphaactinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol. 2007;43:429-436. (Pubitemid 47451426)
29. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation. 2010;122:2039-2047.
30. Takahashi K, Hiwada K, Kokubu T. Vascular smooth muscle calponin. A novel troponin T-like protein. Hypertension. 1988;11:620-626.
31. Takahashi K, Nadal-Ginard B. Molecular cloning and sequence analysis of smooth muscle calponin. J Biol Chem. 1991;266:13284-13288. (Pubitemid 21907341)
32. Kim HR, Appel S, Vetterkind S, Gangopadhyay SS, Morgan KG. Smooth muscle signalling pathways in health and disease. J Cell Mol Med. 2008;12:2165-2180.
33. Walsh MP, Carmichael JD, Kargacin GJ. Characterization and confocal imaging of calponin in gastrointestinal smooth muscle. Am J Physiol. 1993;265:C1371-C1378. (Pubitemid 2015570)
34. Menice CB, Hulvershorn J, Adam LP, Wang CA, Morgan KG. Calponin and mitogen-activated protein kinase signaling in differentiated vascular smooth muscle. J Biol Chem. 1997;272:25157-25161. (Pubitemid 27415700)
35. Winder SJ, Walsh MP. Smooth muscle calponin. Inhibition of actomyosin MgATPase and regulation by phosphorylation. J Biol Chem. 1990;265: 10148-10155.
36. Winder SJ, Allen BG, Clement-Chomienne O, Walsh MP. Regulation of smooth muscle actin-myosin interaction and force by calponin. Acta Physiol Scand. 1998;164:415-426. (Pubitemid 29015661)
37. Masuki S, Takeoka M, Taniguchi S, Yokoyama M, Nose H. Impaired arterial pressure regulation during exercise due to enhanced muscular vasodilatation in calponin knockout mice. J Physiol. 2003;553:203-212. (Pubitemid 37483928)
38. Tang DC, Kang HM, Jin JP, Fraser ED, Walsh MP. Structure-function relations of smooth muscle calponin. The critical role of serine 175. J Biol Chem. 1996;271:8605-8611. (Pubitemid 26123274)
39. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
40. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum. 1999;42:1140-1146. (Pubitemid 29268950)
41. Yamada A, Uegaki A, Nakamura T, Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharideinduced proteolycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000;49:144-146. (Pubitemid 30262710)
42. Cho WJ, Daniel EE. Colocalization between caveolin isoforms in the intestinal smooth muscle and interstitial cells of Cajal of the Cav1(α/β) and Cav1 (-/-) mouse. Histochem Cell Biol. 2006;126:9-16. (Pubitemid 43882535)
43. Sharma V, Abraham T, So A, Allard MF, McNeill JH. Functional effects of protein kinases and peroxynitrite on cardiac carnitine palmitoyltransferase-1 in isolated mitochondria. Mol Cell Biochem. 2009;337:223-237.
44. Sadowski T, Steinmeyer J. Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol. 2001;28:336-340. (Pubitemid 32165143)
45. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci US A. 1996;93:14014-14019. (Pubitemid 26424237)
46. Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. Faseb J. 2004;18:690-692.
47. Cho WJ, Chow AK, Schulz R, Daniel EE. Matrix metalloproteinase-2, caveolins, focal adhesion kinase and c-Kit in cells. J Cell Mol Med. 2007;11:1069-1086. (Pubitemid 350037049)
48. Rozenblum GT, Gimona M. Calponins: adaptable modular regulators of the actin cytoskeleton. Int J Biochem Cell Biol. 2008;40:1990-1995. (Pubitemid 352004269)